Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: a retrospective study
- 3 Downloads
Alternative anti-androgen therapy (AAT) with flutamide after combined androgen blockade (CAB) therapy with bicalutamide for metastatic prostate cancer is common. However, no studies have compared enzalutamide without AAT with enzalutamide after AAT with flutamide as treatment for castration-resistant prostate cancer (CRPC). We aimed to compare the efficacies of flutamide and enzalutamide for CRPC.
In our hospital, 55 patients were diagnosed with CRPC after CAB therapy and administered flutamide or enzalutamide between May 2014 and December 2017. Patients with flutamide failure were administered enzalutamide. We evaluated the (1) prostate-specific antigen (PSA) best response with initial therapy, (2) PSA progression-free survival with initial therapy (PSA-PFS), (3) PSA best response with enzalutamide therapy, (4) PSA-PFS of enzalutamide therapy, and (5) overall survival (OS).
As first-line therapy, patients were administered enzalutamide (n = 29) or flutamide (n = 26). In the flutamide group, 18 patients showed disease progression and were administered enzalutamide. PSA best response was statistically higher in the enzalutamide group. PSA-PFS was significantly longer in the enzalutamide group [hazard ratio (HR) 0.42, 95% confidence interval (CI) 0.19–0.92, p = 0.024]. However, there was no significant difference in PSA best response with enzalutamide therapy and PSA-PFS between the first- and second-line enzalutamide therapies (HR 0.80, 95% CI 0.33–1.94, p = 0.62). There was no significant difference in OS between enzalutamide and flutamide groups (HR 1.85, 95% CI 0.53–6.42, p = 0.33).
AAT with subsequent flutamide after CAB therapy with bicalutamide may be suitable for some CRPC patients.
KeywordsCastration-resistant prostate cancer Enzalutamide Flutamide
The authors wish to thank the following collaborators for help with patient care: Dr. Katsuyuki Kuratsukuri, Dr. Nobuyuki Kuwabara, and Dr. Tomoaki Iwai.
Compliance with ethical standards
Conflict of interest
Taro Iguchi, Sayaka Yasuda, and Tatsuya Nakatani received a research grant from Astellas Pharma Inc. and Bayer Yakuhin, Ltd.; Taro Iguchi received lecture fees from Astellas Pharma Inc., Bayer Yakuhin, Ltd. Janssen Pharmaceutical K.K., and Sanofi K.K.; Satoshi Tamada, Minoru Kato, Taiyo Otoshi, Kosuke Hamada, and Takeshi Yamasaki have no conflict of interest.
- 15.Kim CS, Choi YD, Lee SE et al (2017) Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naive, metastatic castration-resistant prostate cancer. Medicine 96(27):e7223. https://doi.org/10.1097/md.0000000000007223 CrossRefGoogle Scholar
- 17.Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26(7):1148–1159. https://doi.org/10.1200/JCO.2007.12.4487 CrossRefGoogle Scholar
- 19.Momozono H, Miyake H, Tei H et al (2016) Clinical outcomes of anti-androgen withdrawal and subsequent alternative anti-androgen therapy for advanced prostate cancer following failure of initial maximum androgen blockade. Mol Clin Oncol 4(5):839–844. https://doi.org/10.3892/mco.2016.817 CrossRefGoogle Scholar
- 24.Zhao JG, Liu JD, Shen PF et al (2018) Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world retrospective study. Asian J Androl 20(6):545–550. https://doi.org/10.4103/aja.aja_58_18 CrossRefGoogle Scholar